Drug Trial Radar · NCT05987423
Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease
Last checked: Nov 20, 2026Latest source record: Jul 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
131
Actual
Start
Oct 26, 2023
Primary completion
Jul 8, 2025
Study completion Jun 25, 2026
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Aug 14, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of subcutaneous (SC) satralizumab, a recombinant, humanized anti-interleukin-6 (IL-6) receptor monoclonal antibody, in participants with thyroid eye disease (TED).
Conditions
- Thyroid Eye Disease
- TED
Interventions
SatralizumabDrug
Satralizumab will be administered by SC injection.
PlaceboDrug
Placebo will be administered by SC injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants in the Active TED Population Who Achieved ≥ 2 Millimeters (mm) Reduction in Proptosis From Baseline at Week 24 in the Study EyeTime frame: At Week 24
Locations
46 sites in 10 countries. Site status is shown where the registry gives one.
Thrive Health Research LLC
Beverly Hills, California
UCSD Shiley Eye Center
La Jolla, California
Grene Vision Group, LLC
Wichita, Kansas
Johns Hopkins University
Baltimore, Maryland
University of Michigan, Kellogg Eye Center
Ann Arbor, Michigan
Great Lakes Eye Care
Saint Joseph, Michigan
'Northwell Health Physician Partners Ophthalmology
Great Neck, New York
EyeHealth Northwest
Portland, Oregon
Austin Retina Associates
Austin, Texas
Eyelid Center of Utah
Salt Lake City, Utah
WVU Eye Institute
Morgantown, West Virginia
Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada
Buenos Aires, Argentina
Centro Oftalmologico Dr. Charles S.A.
Capital Federal, Argentina
Oftalmos
Capital Federal, Argentina
Buenos Aires Mácula
Ciudad Autonoma Buenos Aires, Argentina
Centrovision Mendoza
Mendoza, Argentina
Grupo Laser Vision
Rosario, Argentina
Sydney Eye Hospital
Sydney, New South Wales, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Centre For Eye Research Australia
East Melbourne, Victoria, Australia
Medizinische Universitat Wien
Vienna, Austria
Charité-Universitätsmedizin Berlin, Campus Virchow Klinikum
Berlin, Germany
Universitätsklinikum Carl Gustav Carus, Klinik und Poliklinik für Augenheilkunde
Dresden, Germany
Universitätsklinikum Essen
Essen, Germany
Universitätsklinikum Freiburg, Klinik für Augenheilkunde
Freiburg im Breisgau, Germany
Universitatsklinikum Munster
Münster, Germany
Universitäts-Augenklinik Tübingen
Tübingen, Germany
Hong Kong Eye Hospital
Mong Kok, Hong Kong
Budapest Retina Associates Kft.
Budapest, Hungary
A.O. U. Federico II
Naples, Campania, Italy
Fondazione Policlinico Universitario A Gemelli
Rome, Lazio, Italy
Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
Milan, Lombardy, Italy
Ospedale Di Circolo E Fondazione Macchi
Varese, Lombardy, Italy
Azienda Ospedaliero Universitaria Pisana
Pisa, Tuscany, Italy
Aichi Medical University Hospital
Aichi, Japan
Kyushu University Hospital
Fukuoka, Japan
Social Medical Corporation Tenjinkai Shinkoga Hospital
Fukuoka, Japan
Hokkaido University Hospital
Hokkaido, Japan
Kobe Kaisei Hospital Medical foundation
Hyōgo, Japan
Hospital of the University of Occupational and Environmental Health,Japan
Kitakyushu-shi, Japan
Showing 40 of 46 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.